191 related articles for article (PubMed ID: 19180240)
1. Towards predictive computational models of oncolytic virus therapy: basis for experimental validation and model selection.
Wodarz D; Komarova N
PLoS One; 2009; 4(1):e4271. PubMed ID: 19180240
[TBL] [Abstract][Full Text] [Related]
2. ODE models for oncolytic virus dynamics.
Komarova NL; Wodarz D
J Theor Biol; 2010 Apr; 263(4):530-43. PubMed ID: 20085772
[TBL] [Abstract][Full Text] [Related]
3. Complex spatial dynamics of oncolytic viruses in vitro: mathematical and experimental approaches.
Wodarz D; Hofacre A; Lau JW; Sun Z; Fan H; Komarova NL
PLoS Comput Biol; 2012; 8(6):e1002547. PubMed ID: 22719239
[TBL] [Abstract][Full Text] [Related]
4. Computational modeling approaches to studying the dynamics of oncolytic viruses.
Wodarz D
Math Biosci Eng; 2013 Jun; 10(3):939-57. PubMed ID: 23906157
[TBL] [Abstract][Full Text] [Related]
5. Permissiveness of human cancer cells to oncolytic bovine herpesvirus 1 is mediated in part by KRAS activity.
Cuddington BP; Mossman KL
J Virol; 2014 Jun; 88(12):6885-95. PubMed ID: 24696490
[TBL] [Abstract][Full Text] [Related]
6. The replicability of oncolytic virus: defining conditions in tumor virotherapy.
Tian JP
Math Biosci Eng; 2011 Jul; 8(3):841-60. PubMed ID: 21675814
[TBL] [Abstract][Full Text] [Related]
7. Oncolytic potency and reduced virus tumor-specificity in oncolytic virotherapy. A mathematical modelling approach.
Mahasa KJ; Eladdadi A; de Pillis L; Ouifki R
PLoS One; 2017; 12(9):e0184347. PubMed ID: 28934210
[TBL] [Abstract][Full Text] [Related]
8. Functional interactions of antiapoptotic proteins and tumor necrosis factor in the context of a replication-competent adenovirus.
Liu TC; Wang Y; Hallden G; Brooks G; Francis J; Lemoine NR; Kirn D
Gene Ther; 2005 Sep; 12(17):1333-46. PubMed ID: 15920462
[TBL] [Abstract][Full Text] [Related]
9. Modelling heterogeneity in viral-tumour dynamics: The effects of gene-attenuation on viral characteristics.
Jenner A; Yun CO; Yoon A; Kim PS; Coster ACF
J Theor Biol; 2018 Oct; 454():41-52. PubMed ID: 29857083
[TBL] [Abstract][Full Text] [Related]
10.
Jung MY; Offord CP; Ennis MK; Kemler I; Neuhauser C; Dingli D
Cancer Res; 2018 Oct; 78(20):5992-6000. PubMed ID: 30115692
[TBL] [Abstract][Full Text] [Related]
11. Multiscale moving boundary modelling of cancer interactions with a fusogenic oncolytic virus: The impact of syncytia dynamics.
Alzahrani T; Eftimie R; Trucu D
Math Biosci; 2020 May; 323():108296. PubMed ID: 31887267
[TBL] [Abstract][Full Text] [Related]
12. Luciferase imaging for evaluation of oncolytic adenovirus replication in vivo.
Guse K; Dias JD; Bauerschmitz GJ; Hakkarainen T; Aavik E; Ranki T; Pisto T; Särkioja M; Desmond RA; Kanerva A; Hemminki A
Gene Ther; 2007 Jun; 14(11):902-11. PubMed ID: 17377596
[TBL] [Abstract][Full Text] [Related]
13. Computational modeling approaches to the dynamics of oncolytic viruses.
Wodarz D
Wiley Interdiscip Rev Syst Biol Med; 2016 May; 8(3):242-52. PubMed ID: 27001049
[TBL] [Abstract][Full Text] [Related]
14. Quantitative imaging and dynamics of tumor therapy with viruses.
Kemler I; Karamched B; Neuhauser C; Dingli D
FEBS J; 2021 Nov; 288(21):6273-6285. PubMed ID: 34213827
[TBL] [Abstract][Full Text] [Related]
15. A mathematical model of oncolytic virotherapy with time delay.
Wang ZZ; Guo ZM; Smith H
Math Biosci Eng; 2019 Mar; 16(4):1836-1860. PubMed ID: 31137188
[TBL] [Abstract][Full Text] [Related]
16. Optimal Control Model of Tumor Treatment with Oncolytic Virus and MEK Inhibitor.
Su Y; Jia C; Chen Y
Biomed Res Int; 2016; 2016():5621313. PubMed ID: 28097139
[TBL] [Abstract][Full Text] [Related]
17. Oncolytic adenoviruses - selective retargeting to tumor cells.
Mathis JM; Stoff-Khalili MA; Curiel DT
Oncogene; 2005 Nov; 24(52):7775-91. PubMed ID: 16299537
[TBL] [Abstract][Full Text] [Related]
18. Questing for an optimal, universal viral agent for oncolytic virotherapy.
Paiva LR; Martins ML; Ferreira SC
Phys Rev E Stat Nonlin Soft Matter Phys; 2011 Oct; 84(4 Pt 1):041918. PubMed ID: 22181186
[TBL] [Abstract][Full Text] [Related]
19. Crosstalk between oncolytic viruses and autophagy in cancer therapy.
Jin KT; Tao XH; Fan YB; Wang SB
Biomed Pharmacother; 2021 Feb; 134():110932. PubMed ID: 33370632
[TBL] [Abstract][Full Text] [Related]
20. To Infection and Beyond: The Multi-Pronged Anti-Cancer Mechanisms of Oncolytic Viruses.
Cassady KA; Haworth KB; Jackson J; Markert JM; Cripe TP
Viruses; 2016 Feb; 8(2):. PubMed ID: 26861381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
